Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14440476 | 1.00 | CHRNB4 (0.31) | CHRNB4CHRNA3CHRNA1ESR1CHRNG | |
| SCHEMBL7698489 | 0.77 | PDE10A (0.31) | PDE10A | |
| SCHEMBL2741393 | 0.75 | CHRNB2 (0.56) | CHRNB4CHRNA3CHRNA1ESR1CHRNG | |
| SCHEMBL13561410 | 0.75 | CHRNB2 (0.56) | CHRNB4CHRNA3CHRNA1ESR1CHRNG | |
| SCHEMBL14003843 | 0.75 | CHRNB2 (0.56) | CHRNB4CHRNA3CHRNA1ESR1CHRNG | |
| SCHEMBL3831037 | 0.70 | CHRNB2 (0.40) | CHRNB4CHRNA3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL14002204 | 0.70 | — | — | |
| SCHEMBL13075977 | 0.70 | OPRM1 (0.36) | HTR3A | |
| Hydrochloric Acid SCHEMBL4819236 | 0.69 | CHRNB2 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL18136226 | 0.69 | KAT2B (0.38) | HTR3APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185327-A1 | Preparation of substituted quinoxalines | PFIZER INC | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185327-A1 | Preparation of substituted quinoxalines | QDPR, DDT, NQO2 | CHRNB4 442/4885CHRNA3 116/4885CHRNA1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.